Health Department Eases Rules on Unproven Peptide Injections

The Department of Health and Human Services posted a draft policy on Wednesday that reduces regulatory barriers for injectable peptides used in the wellness industry. The move comes amid a trend toward alternative health treatments that have gained traction in political and commercial circles.

The document specifically addresses six chemicals, including BPC-157, TB-500, and KPV. These substances are marketed for purposes such as building muscle, healing injuries, and increasing energy. Under standard Federal Food and Drug Administration rules, these products are considered illegal drugs because they have not completed the agency's review process for safety and effectiveness.

The policy directs the FDA to refrain from taking action against specialty pharmacies that sell these specific compounds. Health Secretary Robert F. Kennedy Jr. stated that the change advances patient choice and protects consumers from unscreened ingredients sold online. He has previously described himself as a big fan of peptides and shared his personal use of BPC-157 for a muscle injury.

Internal sources indicate that FDA scientific staffers opposed the shift. Six people familiar with the deliberations told The Associated Press that the agency's scientists warned the policy could undermine its mission to keep unproven products off the market. The final draft represents a compromise from an earlier HHS plan, which sought to formally designate the peptides as safe for compounding. FDA staff rejected that stronger approach due to safety concerns.

The new guidance includes technical safeguards, such as requiring pharmacies to source ingredients from FDA-registered factories and collect data on side effects. However, Dr. Peter Lurie, who leads the Center for Science in the Public Interest, noted that the FDA lacks legal authority to enforce these specific pharmacy requirements. He also questioned the timing of the release, which occurred days before the midterm election.

The peptide market has attracted major telehealth providers like Hims & Hers, with Wall Street analysts valuing the sector at more than $2 billion. Lee Rosebush of the American Academy of Peptide Medicine called the move a huge step for medical freedom. The Alliance for Pharmacy Compounding is seeking clarification on how the federal policy will interact with state pharmacy regulations.

In 2023, the FDA added more than a dozen peptides to a list of substances that should not be compounded due to risks of allergic reactions, kidney damage, and tumor growth. A panel of outside experts selected by HHS voted in July to drop restrictions on the six peptides named in the new document.